Results 41 to 50 of about 5,684 (155)

Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy : Further Analyses From ATTR-ACT

, 2021
Objectives: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), this study aimed to determine whether there is a differential effect between variant transthyretin amyloidosis (ATTRv) and wild-type transthyretin (ATTRwt)
Velazquez, Eric J., Nativi-Nicolau, Jose, Boman, Kurt, Damy, Thibaud,, Nativi-Nicolau, Jose,, Maurer, Mathew S., Sultan, Marla B., Velazquez, Eric J.,, Elliott, Perry,, Rapezzi, Claudio, Sultan, Marla B.,, Schwartz, Jeffrey H.,, Rapezzi, Claudio,, Boman, Kurt,, Elliott, Perry, Patterson, Terrell A., Damy, Thibaud, Berk, John L., Gundapaneni, Balarama,, Schwartz, Jeffrey H., Berk, John L.,, Patterson, Terrell A.,, Maurer, Mathew S.,, Gundapaneni, Balarama, Patterson T. A., Rapezzi C., Sultan M. B., Velazquez E. J., Boman K., Gundapaneni B., Schwartz J. H., Berk J. L., Elliott P., Nativi-Nicolau J., Maurer M. S., Damy T.   +35 more
core   +2 more sources

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Old disease, new twist

Journal of Hospital Medicine, EarlyView.
Abstract An 81‐year‐old man with a history of high‐grade urothelial carcinoma of the bladder and ureter on treatment with atezolizumab and tiragolumab presented to the emergency department with 5 months of malaise, generalized weakness, and fatigue and 2 weeks of subjective fevers. One month prior to presentation, he received an empiric 9‐day course of
Hadi Roudsari, Gurpreet Dhaliwal, Anand D. Jagannath, Alan H. Baik, Sam Brondfield   +4 more
wiley   +1 more source

A study protocol for an observational cohort investigating cardiac transthyretin amyloidosis flow reserve before and after Tafamidis treatment: The AMYTRE study

Frontiers in Medicine, 2022
IntroductionAnginal symptoms and signs of ischemia have been reported in some patients with cardiac transthyretin amyloidosis (ATTR) without obstructive epicardial coronary artery disease (CAD).
Bastien Vançon, Arnaud Bisson, Arnaud Bisson, Arnaud Bisson, Maxime Courtehoux, Anne Bernard, Anne Bernard, Matthieu Bailly, Matthieu Bailly   +8 more
doaj   +1 more source

Feasibility of Left Bundle Branch Pacing and Management of Jailed Leads After Transcatheter Tricuspid Valve Implantation

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Atrioventricular conduction disturbances and the need for cardiac implantable electronic device (CIED) therapy are frequently required after transcatheter tricuspid valve implantation (TTVI). The interaction between the annulus, transcatheter heart valve and the leads is often complex and the optimal management under debate.
Thomas Seiler, Andreas Haeberlin, Domenico Angellotti, Joanna Bartkowiak, Nikola Kozhuharov, Boldizsar Kovacs, Stephan Windecker, Tobias Reichlin, Fabien Praz, Fabian Noti   +9 more
wiley   +1 more source

Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy [PDF]

Publisher Copyright: © 2025 The AuthorsBackground: Tafamidis is a standard of care treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
Drachman, Brian M., Damy, Thibaud, Maurer, Mathew S., Ebede, Ben, Wang, Ronnie, Crespo-Leiro, Maria G., Marino, Valentina, Delgado, Diego, Hanna, Mazen, Garcia-Pavia, Pablo   +9 more
core   +1 more source

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials

Frontiers in Cardiovascular Medicine, 2023
An increasing awareness of the disease, new diagnostic tools and novel therapeutic opportunities have dramatically changed the management of patients with amyloid transthyretin cardiomyopathy (ATTR-CM).
Daniela Tomasoni, Giovanni Battista Bonfioli, Alberto Aimo, Alberto Aimo, Marianna Adamo, Marco Canepa, Marco Canepa, Riccardo M. Inciardi, Carlo Mario Lombardi, Matilde Nardi, Matteo Pagnesi, Mauro Riccardi, Giuseppe Vergaro, Giuseppe Vergaro, Enrico Vizzardi, Michele Emdin, Michele Emdin, Marco Metra   +17 more
doaj   +1 more source

Cardiac Amyloidosis Treatment

Methodist DeBakey Cardiovascular Journal, 2022
Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications.
Lily K. Stern, Jignesh Patel
doaj   +1 more source

Neuropathy in Val122Ile Hereditary Transthyretin (ATTR) Amyloidosis: A Multicenter Retrospective Cohort Study

Journal of the Peripheral Nervous System, Volume 31, Issue 3, September 2026.
ABSTRACT Background and Aims The Val122Ile ATTR Amyloidosis has traditionally been linked to cardiac manifestations. Recent studies suggest that neuropathy may be relevant. In this study, we characterized its peripheral nerve manifestations in depth. Methods This was a national, multicenter, observational, retrospective study.
Anna Paula Paranhos, Marcela Câmara Machado Costa, Carolina Lavigne Moreira, Diogo Fernandes dos Santos, Marcondes Cavalcante França, Renan Flavio de França Nunes, Osvaldo José Moreira do Nascimento, Jemima Araujo da Silva Batista, Eduardo Boiteux Uchôa Cavalcanti, Cleonisio Leite Rodrigues, Ândrea Virgínia Ferreira Chaves, Marcelo Soares Kerstenetzky, Lara Albuquerque de Brito, Carlo Domênico Marrone, Marcus Vinicius Magno Gonçalves, Pedro José Tomaselli, Wilson Marques   +16 more
wiley   +1 more source

Impact of Baseline Polyneuropathy Severity on Eplontersen Efficacy in the NEURO‐TTRansform Clinical Trial

Journal of the Peripheral Nervous System, Volume 31, Issue 3, September 2026.
ABSTRACT Background and Aims In the NEURO‐TTRansform clinical trial (NCT04136184), eplontersen improved neuropathy impairment and quality of life (QoL) through Week 66 versus the NEURO‐TTR historical placebo in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv‐PN).
Thomas H. Brannagan III, Markus Weiler, Márcia Waddington Cruz, Sami Khella, John L. Berk, Morie Gertz, Ahmad Masri, Mathew S. Maurer, Jonas Wixner, Jonatan Nåtman, T. Jesse Kwoh, Maksym Pola, Laura Obici   +12 more
wiley   +1 more source